Lometrexol (hydrate)

1435784-14-7

461.47

DMSO : 40 mg/mL (86.68 mM; Need ultrasonic and warming)

Apoptosis; Cell Cycle/DNA Damage

Lometrexol hydrate (DDATHF hydrate), an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol hydrate can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol hydrate has anticancer activity^[1][2]. Lometrexol hydrate also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor^[3]. IC50 & Target: GARFT^[1] In Vitro: Lometrexol hydrate (DDATHF hydrate) binds tightly to GART, resulting in a rapid and prolonged depletion of intracellular purine ribonucleotides^[2].
Lometrexol hydrate (1-30 uM; 2-10 hours) induces rapid and complete growth inhibition in L1210 cells^[2].
Lometrexol hydrate (1 uM; 2-24 hours) induces cell cycle arrest in murine leukemia L1210 cells^[2].
Lometrexol hydrate induces abnormal proliferation and apoptosis exist in neural tube defects (NTDs)^[1].
In Vivo: Lometrexol hydrate (DDATHF hydrate; i.p.; 15-60 mg/kg; on gestation day 7.5) increases the rate of embryonic resorption and growth retardation in a dose-dependent manner^[1].
Lometrexol hydrate (i.p.; 40 mg/kg) maximally inhibits GARFT activity after at 6 hours and thereafter gradually increases with time but remains significantly lower than control even at 96 hours. Levels of ATP, GTP, dATP and dGTP of NTDs embryonic brain tissue decreases significantly at 6 h, and more significantly over time^[1].